KA-3458 / KYinno - LARVOL DELTA

The bispecific antibody KA-3458, targeting CD38 and CD28, specifically enhances T cell activation within the tumor microenvironment (AACR 2025) - "Toxicity studies are currently underway. In conclusion, KA-3458, developed using our common light chain bispecific antibody discovery platform, shows great potential as a preclinical candidate for the treatment of relapsed/refractory B-cell lymphoma and multiple myeloma."

Biomarker • Tumor microenvironment • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL6